195 related articles for article (PubMed ID: 9776407)
1. Tamoxifen debate hinges on whose risk is high enough.
Reynolds T
J Natl Cancer Inst; 1998 Oct; 90(19):1428-30. PubMed ID: 9776407
[No Abstract] [Full Text] [Related]
2. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
3. Breast cancer biology blossoms in the clinic.
Nass SJ; Hahm HA; Davidson NE
Nat Med; 1998 Jul; 4(7):761-2. PubMed ID: 9662357
[No Abstract] [Full Text] [Related]
4. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Ziegler J
J Natl Cancer Inst; 1996 Aug; 88(16):1100-2. PubMed ID: 8757185
[No Abstract] [Full Text] [Related]
5. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
6. Gynaecological aspects of tamoxifen treatment in breast cancer patients.
Obwegeser R; Auerbach L; Kubista E
Cancer Treat Rev; 1997; 23(5-6):289-304. PubMed ID: 9465881
[No Abstract] [Full Text] [Related]
7. [Tamoxifen and breast cancer: is everything known already?].
Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
[No Abstract] [Full Text] [Related]
8. Tamoxifen.
Nurs Times; 2006 Feb 21-27; 102(8):33. PubMed ID: 16519033
[No Abstract] [Full Text] [Related]
9. Tamoxifen and menopausal status: risks and benefits.
Sasco AJ
Lancet; 1996 Mar; 347(9003):761. PubMed ID: 8602018
[No Abstract] [Full Text] [Related]
10. Tamoxifen therapy--long-term results and complications.
Moore MP; Kinne DW
Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
[No Abstract] [Full Text] [Related]
11. Breast cancer highlights.
Kuter I
Oncologist; 1999; 4(4):299-308. PubMed ID: 10476541
[No Abstract] [Full Text] [Related]
12. Second cancers after adjuvant tamoxifen therapy for breast cancer.
Curtis RE; Boice JD; Shriner DA; Hankey BF; Fraumeni JF
J Natl Cancer Inst; 1996 Jun; 88(12):832-4. PubMed ID: 8637050
[No Abstract] [Full Text] [Related]
13. Tamoxifen in early breast cancer.
Saibara T; Ogawa Y; Onishi S
Lancet; 1998 Aug; 352(9125):404. PubMed ID: 9717954
[No Abstract] [Full Text] [Related]
14. Should tamoxifen users be screened for endometrial lesions?
Neven P; Vergote I
Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
[No Abstract] [Full Text] [Related]
15. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
16. Chemoprevention of breast cancer: recommendations and rationale.
Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
[No Abstract] [Full Text] [Related]
17. One step forward or one step back with tamoxifen?
Gelmon K
Lancet; 2000 Sep; 356(9233):868-9. PubMed ID: 11036885
[No Abstract] [Full Text] [Related]
18. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
19. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
20. STAR trial reports.
Eur J Cancer; 2006 Aug; 42(12):1694. PubMed ID: 16998956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
